Incyte Corporation [NASDAQ: INCY] loss -1.61% on the last trading session, reaching $90.56 price per share at the time. The company report on December 30, 2020 that Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804.
– Incyte and Cellenkos will evaluate the combination of ruxolitinib (Jakafi®) and CK0804, cord blood-derived T-regulatory cells, in patients with myelofibrosis.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
– Incyte has an exclusive option to acquire sole rights to CK0804.
Incyte Corporation represents 218.78 million in outstanding shares, while the company has a total market value of $20.13 billion with the latest information. INCY stock price has been found in the range of $89.32 to $92.52.
If compared to the average trading volume of 1.12M shares, INCY reached a trading volume of 928849 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Incyte Corporation [INCY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INCY shares is $105.69 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INCY stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Incyte Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 07, 2021. The new note on the price target was released on January 04, 2021, representing the official price target for Incyte Corporation stock. On May 06, 2020, analysts increased their price target for INCY shares from 89 to 99.
The Average True Range (ATR) for Incyte Corporation is set at 2.67, with the Price to Sales ratio for INCY stock in the period of the last 12 months amounting to 8.19. The Price to Book ratio for the last quarter was 8.29, with the Price to Cash per share for the same quarter was set at 7.80.
Trading performance analysis for INCY stock
Incyte Corporation [INCY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.49. With this latest performance, INCY shares gained by 4.97% in over the last four-week period, additionally sinking by -13.02% over the last 6 months – not to mention a rise of 12.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INCY stock in for the last two-week period is set at 56.13, with the RSI for the last a single of trading hit 54.59, and the three-weeks RSI is set at 55.42 for Incyte Corporation [INCY]. The present Moving Average for the last 50 days of trading for this stock 85.51, while it was recorded at 92.59 for the last single week of trading, and 93.07 for the last 200 days.
Incyte Corporation [INCY]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Incyte Corporation [INCY] shares currently have an operating margin of +19.53 and a Gross Margin at +93.18. Incyte Corporation’s Net Margin is presently recorded at +20.70.
Return on Total Capital for INCY is now 18.28, given the latest momentum, and Return on Invested Capital for the company is 19.49. Return on Equity for this stock inclined to 19.76, with Return on Assets sitting at 14.72. When it comes to the capital structure of this company, Incyte Corporation [INCY] has a Total Debt to Total Equity ratio set at 2.77. Additionally, INCY Total Debt to Total Capital is recorded at 2.70, with Total Debt to Total Assets ending up at 2.10. Long-Term Debt to Equity for the company is recorded at 1.68, with the Long-Term Debt to Total Capital now at 1.64.
Reflecting on the efficiency of the workforce at the company, Incyte Corporation [INCY] managed to generate an average of $306,941 per employee. Receivables Turnover for the company is 7.00 with a Total Asset Turnover recorded at a value of 0.71.Incyte Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.50 and a Current Ratio set at 3.60.
Incyte Corporation [INCY]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Incyte Corporation posted 0.65/share EPS, while the average EPS was predicted by analysts to be reported at 0.57/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 14.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INCY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Incyte Corporation go to 25.85%.
An analysis of insider ownership at Incyte Corporation [INCY]
There are presently around $18,221 million, or 94.80% of INCY stock, in the hands of institutional investors. The top three institutional holders of INCY stocks are: BAKER BROS. ADVISORS LP with ownership of 31,999,398, which is approximately 0.001% of the company’s market cap and around 0.40% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 30,913,505 shares of the stock with an approximate value of $2.8 billion in INCY stocks shares; and VANGUARD GROUP INC, currently with $1.86 billion in INCY stock with ownership of nearly -1.173% of the company’s market capitalization.
Positions in Incyte Corporation stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 241 institutional holders increased their position in Incyte Corporation [NASDAQ:INCY] by around 7,619,685 shares. Additionally, 246 investors decreased positions by around 10,456,875 shares, while 67 investors held positions by with 183,129,410 shares. The mentioned changes placed institutional holdings at 201,205,970 shares, according to the latest SEC report filing. INCY stock had 64 new institutional investments in for a total of 1,909,342 shares, while 66 institutional investors sold positions of 1,075,175 shares during the same period.